3 Treatments for FIP in Cats

Updated: Jul 15



Let us begin by stating that No Treatment Can Guarantee 100% Cure of FIP in cats. Whether you cat recovers from FIP depends greatly on the following:

  • timeliness of the treatment

  • completeness of treatment, including treating FIP related complications

  • breed

  • age

  • pre-existing conditions and overall health,

  • diet

  • living environment

  • brand of GS-441 used

  • dosage used

  • cat's will to live.  

What is certain is that the earlier FIP infection is detected and treated, the higher chance of treatment success.  This is backed by data from hundreds of cats that we have treated. Thus, we implore all owners to treat FIP in cat as soon as can.

GS-441524


GS-441524 is currently the best FIP treatment available, with demonstrated clinical efficacy greater than 80% (This is the reason why we only offer this treatment).  The journey of GS-441524 began with Gilead Sciences' (NASDAQ: GILD) investigation into drugs that can treat human infectious diseases such as the Ebola and SARS (severe acute respiratory syndrome).


The intense research into human treatments leads to the breakthrough discovery by a team of scientists lead by Dr. Niel Pederson of GS's effectiveness in treat Feline infectious peritonitis (FIP) in cats. It is estimated that FIP kills up to 1.4% of cats around the world.




We summarised Dr. Niel Pederson and his team's published clinical study below. You can read the clinic study by click here.


Reported Observations:

  1. Symptoms of neurological involvement: reluctant or no longer able to jump to higher space.

  2. Symptoms of FIP:

  • Effusive – thoracic/abdominal. Thoracic effusion with dyspneic required prior pleural effusion removal before treatment.

  • Non-effusive - disease localized to the abdomen (mesenteric and ileo/cecal/colic lymph nodes)/chest (lungs, hilar lymph nodes), could progress to effusive form.

Treatment Outcomes:

  1. Fever resolves within 12-36 h.

  2. Daily improvement in appetite, activity levels and weight gain.

  3. Abdominal effusion disappeared from 10-14 days onwards over a 1-2weeks time.

  4. Residual dyspnea and thoracic effusion not apparent after 7 days.

  5. Jaundice resolved and hyperbilirubinemia decreased over 2-4 weeks.

  6. Ocular disease began to clear within 24-48 h and no longer apparent by 7-14 days.

  7. Enlarged mesenteric and ileo/cecal/colic lymph nodes slowly decreased in size over the course of the treatment.

  8. Cats because outwardly normal after 2 weeks of treatment.

Statistics

  1. 4/31 cats died of severe diseases/complications

  2. 1/31 cat died of non-responding to treatment

  3. 1/26 cat relapse during the 12 weeks treatment (rise in blood urea and serum levels of symmetric dimethylarginine (SDMA).

  4. 8/26 cat relapse between 3-84 days (average 23 days).

  5. 2/8 cats relapsed of a neurological nature (high fever and severe posterior ataxia and incoordination)

  6. 6/8 with fever, anorexia and lack of activity.

  7. 1/8 with abdominal effusion

  8. 3/26 cats have problems with injections and skin reaction, interrupted treatment.

  9. Interrupting treatment course cause relapse (3/3).


Thirty-one cats, ranging in age from 3-73 months, were enrolled in the study, and 26 completed the planned 12 weeks or more of treatment; the remainder died or were euthanised due to their severe disease.


For these 26 cats, the clinical response was dramatic: fever usually resolved within 12-36 h, concurrent with a marked improvement in appetite, activity levels and weight gain. In cats with the more common effusive or 'wet' form of FIP, abdominal effusions rapidly disappeared, starting at around 10-14 days after commencing treatment.


Encouragingly, and somewhat unexpectedly, cats with non-effusive ('dry') FIP and older cats responded as well to GS-441524 treatment as did cats with effusive FIP and young cats. The safety profile of GS-441524 was likewise impressive.





24 of the 26 cats remain healthy, with one having succumbed to FIP disease and one to unrelated heart disease. 18 of these cats underwent just one round of treatment; the remaining eight suffered disease relapses, but these were successfully treated with a further (in two cases, a third) round of treatment at a higher dose.




https://www.sciencedaily.com/releases/2019/02/190213100442.htm

https://journals.sagepub.com/doi/pdf/10.1177/1098612X19825701


GC-376


GC-376 seemed promising when it first appeared on the scene, but ultimately proved not ideal in the long term.  In a clinical study 19 of 20 cats treated with GC376 regained outward health within 2 weeks of initial treatment. However, the disease relapses 1-7 weeks after the primary treatment. Upon relapses 13 of these 19 cats were no longer responsive to the GC-376 treatment.  Severe neurologic disease occurred in 8/13 cats that failed treatment and five cats had recurrences of abdominal lesions. 


At the time of the written clinical report, seven cats were in disease remission. Five kittens aged 3.3–4.4 months with wet FIP were treated for 12 weeks and have been in disease remission after stopping treatment and at the time of writing for 5–14 months (mean 11.2 months).


A sixth kitten was in remission for 10 weeks after 12 weeks of treatment, relapsed and is responding to the second round of GC376. The seventh was a 6.8-year-old cat with only mesenteric lymph node involvement that went into remission after three relapses that required progressively longer repeat treatments over a 10 month period.


Side effects of treatment included transient stinging upon injection and occasional foci of subcutaneous fibrosis and hair loss. There were retarded development and an abnormal eruption of permanent teeth in cats treated before 16–18 weeks of age.


You can read more on the GC-376 clinical study here.

INTERFERON

Also called interferon-omega (FeIFN-omega) has demonstrated no effect on survival time or quality of life of cats according to the study conducted in Germany and published in the United States National Library of Medicine.


There was no statistically significant difference in the survival time of cats treated with FeIFN-omega versus placebo or in any other variable evaluated (with the exception of the lymphocyte count). The cats survived between 3 and 200 days (median, 9 days). There was only 1 long-term survivor (> 3 months), and the cat was in the FeIFN-omega group. 


You can read more on the Interferon study here.



Start treatment early.

Learn more about our GS-441524 here: https://www.curefip.com/gs-441524




Published by: curefip.com https://www.facebook.com/fipcure

Share with someone who should read this.

301 views

Recent Posts

See All

QUICK LINKS

FOLLOW US

PAYMENTS

  • YouTube